JP2021518344A5 - - Google Patents
Info
- Publication number
- JP2021518344A5 JP2021518344A5 JP2020548995A JP2020548995A JP2021518344A5 JP 2021518344 A5 JP2021518344 A5 JP 2021518344A5 JP 2020548995 A JP2020548995 A JP 2020548995A JP 2020548995 A JP2020548995 A JP 2020548995A JP 2021518344 A5 JP2021518344 A5 JP 2021518344A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- alkyl
- cancer
- cycloalkyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644189P | 2018-03-16 | 2018-03-16 | |
| US62/644,189 | 2018-03-16 | ||
| PCT/US2019/022727 WO2019178590A1 (en) | 2018-03-16 | 2019-03-18 | Heterocyclic inhibitors of atr kinase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021518344A JP2021518344A (ja) | 2021-08-02 |
| JP2021518344A5 true JP2021518344A5 (enExample) | 2022-03-22 |
| JP7341156B2 JP7341156B2 (ja) | 2023-09-08 |
Family
ID=67904811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548995A Active JP7341156B2 (ja) | 2018-03-16 | 2019-03-18 | Ａｔｒキナーゼの複素環式阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10894052B2 (enExample) |
| EP (1) | EP3765008B1 (enExample) |
| JP (1) | JP7341156B2 (enExample) |
| CN (1) | CN112218631B (enExample) |
| WO (1) | WO2019178590A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| HRP20240368T1 (hr) | 2017-07-13 | 2024-08-30 | Board Of Regents, The University Of Texas System | Heterociklički inhibitori atr kinaze |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| WO2022094218A1 (en) * | 2020-10-29 | 2022-05-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Process for the preparation of heteroaryl-substituted sulfur(vi) compounds |
| EP4332103A4 (en) * | 2021-05-12 | 2025-09-03 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | ATR INHIBITOR COMPOUND CONTAINING A SULFOXIMINE |
| CN117320723A (zh) * | 2021-05-18 | 2023-12-29 | 安康尼克治疗有限公司 | 对parp抑制剂耐药的癌症的治疗剂 |
| WO2023131234A1 (en) * | 2022-01-06 | 2023-07-13 | Shanghai Antengene Corporation Limited | Crystalline forms of an atr inhibitor |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080083188A (ko) | 2006-01-11 | 2008-09-16 | 아스트라제네카 아베 | 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도 |
| WO2008023159A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| CN101563340A (zh) | 2006-09-14 | 2009-10-21 | 阿斯利康(瑞典)有限公司 | 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物 |
| JP2010523637A (ja) | 2007-04-12 | 2010-07-15 | エフ．ホフマン−ラ ロシュ アーゲー | 医薬化合物 |
| WO2008144500A2 (en) | 2007-05-17 | 2008-11-27 | Anadys Pharmaceuticals, Inc. | 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives |
| WO2009007750A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| JP2010533161A (ja) * | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物−９４６ |
| JP2010533158A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物類−９４５ |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| CA2728559A1 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| TW201028410A (en) | 2008-12-22 | 2010-08-01 | Astrazeneca Ab | Chemical compounds 610 |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
| WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
| EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
| WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| LT3418281T (lt) | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| HUE046727T2 (hu) * | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| EP3083618B1 (en) * | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| TWI656121B (zh) * | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| BR112017007708B8 (pt) | 2014-10-13 | 2023-10-24 | Atrin Pharmaceuticals LLC | Composto macrocíclico e composição farmacêutica |
| US10729680B2 (en) * | 2016-01-14 | 2020-08-04 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| WO2017210545A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| HRP20240368T1 (hr) | 2017-07-13 | 2024-08-30 | Board Of Regents, The University Of Texas System | Heterociklički inhibitori atr kinaze |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
-
2019
- 2019-03-18 JP JP2020548995A patent/JP7341156B2/ja active Active
- 2019-03-18 US US16/356,450 patent/US10894052B2/en active Active
- 2019-03-18 WO PCT/US2019/022727 patent/WO2019178590A1/en not_active Ceased
- 2019-03-18 EP EP19767169.6A patent/EP3765008B1/en active Active
- 2019-03-18 CN CN201980019299.6A patent/CN112218631B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531447A5 (enExample) | ||
| JP7696443B2 (ja) | Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
| ES2761824T3 (es) | Compuestos de carboximidamida de benzimidazol y imidazopiridina que tienen actividad como inhibidores de indoleamina 2,3-dioxigenasa | |
| CN109415360B (zh) | 用于抑制shp2活性的化合物和组合物 | |
| ES2539257T3 (es) | Imidazo[1,2-b]piridazinas sustituidas | |
| ES2968252T3 (es) | Compuesto 8,9-dihidroimidazol[1,2-a]pirimido[5,4-e]pirimidin-5(6H)-cetona | |
| ES2392489T3 (es) | Dicarbazoles y procedimientos de uso | |
| US8003662B2 (en) | Heterobicyclic thiophene compounds and methods of use | |
| ES2558780T3 (es) | Imidazopiridazinas como inhibidores de la cinasa Akt | |
| CN115003677A (zh) | 对kras g12d突变具有抑制活性的化合物 | |
| EP3310779A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| JP2022510501A (ja) | 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法 | |
| JP2022515197A (ja) | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 | |
| JP6502332B2 (ja) | 二環式アルキン誘導体およびその使用 | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| RU2018138471A (ru) | Гетероциклические соединения в качестве ингибиторов киназы RET | |
| WO2015157128A1 (en) | Therapuetic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | |
| JP2014503567A5 (enExample) | ||
| ES2918924T3 (es) | Inhibidores de TGF-beta | |
| JP2014502601A (ja) | 置換６，６−縮合窒素複素環化合物及びその使用 | |
| RU2014130129A (ru) | Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| BR112015001528B1 (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
| BR112012011188A2 (pt) | ''composto,composição farmacêutica e uso de um composto" | |
| AU2018319538A1 (en) | Therapeutic heterocyclic compounds | |
| US11529350B2 (en) | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |